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In Brief
Li et al. find that DrAS-Net, a networkbased method, identifies somatic mutation-mediated alternative splicing (AS) and helps prioritize driver mutations. Distinct target AS profiles help explain cancer heterogeneity and classify cancer patients into subtypes with distinct clinical features.
INTRODUCTION
Phenotypic variation and heterogeneity are far more complex in human compared to other species, even though there are similar numbers of genes in the genome. This enigma could be at least partially addressed by studying the extent to which different protein isoforms can be encoded by each genome. It has been increasingly appreciated that alternative splicing is a key factor contributing to protein isoform diversity. In human cancer, for instance, the problem of tumor heterogeneity across patient populations is known to involve alternative splicing. However, the fundamental question of how genomic mutations influence the splicing process leading to cancer is essentially unknown ( Figure 1A ).
Alternative splicing (AS) is a highly regulated process that adds complexity to human transcriptome, proteome, and signal transduction networks in the cell . More than 90% of human protein coding genes produce multiple mRNA isoforms (Wang et al., 2008) ; therefore, AS is one of the main sources of proteomic diversity (Braunschweig et al., 2013) . Tissue-and cell-type-specific AS patterns have been shown to play critical roles in development and differentiation (Buljan et al., 2012; Ellis et al., 2012; Kalsotra and Cooper, 2011; Zhang et al., 2016) . Aberrant AS events have been implicated in complex diseases, including various types of cancer (David and Manley, 2010; Misquitta-Ali et al., 2011; Xu et al., 2014) . AS alterations may confer a selective advantage to the tumor, such as cell proliferation, invasion, and apoptosis evasion (Dominguez et al., 2016; Oltean and Bates, 2014) . The determination of AS deregulation in cancer is therefore of utmost relevance to reveal novel oncogenic mechanisms. Although considerable efforts have been made to study AS alterations in individual cancers, the extent to which aberrant AS perturbations contribute to cancer progression remains largely unknown.
Besides identification of aberrant AS events across cancer types, identifying molecular determinants and mechanisms that perturb AS in cancer is fundamental for the development of cancer-specific biomarkers for prognosis and therapy (Barash et al., 2010; Braunschweig et al., 2013) . Lines of evidence have demonstrated that AS alterations in cancer may be caused by changes in expression, amplification, and deletions in splicing factors and RNA binding proteins (Hollander et al., 2016; Raj et al., 2014; Sebestyé n et al., 2016; Sveen et al., 2016) . Given the complexity of AS events, it is not surprising that they are particularly susceptible to genomic mutations implicated in human cancer (Lu et al., 2012; Maguire et al., 2015; Xing, 2007) . It has been increasingly appreciated that AS events are influenced by genomic mutations. For instance, genetic variants that affect splicing have been inferred by deep learning algorithms , and mutations that lead to intron retention have been identified as a pervasive mechanism by which tumor suppressor genes are inactivated in certain cancers (Jung et al., 2015) . Nevertheless, the general principles by which somatic mutations lead to AS alterations across diverse cancer types are unknown and have the potential to reveal oncogenic mechanisms in diverse cancers.
Functional networks provide an informative platform to investigate properties of cellular systems (Barabá si and Oltvai, 2004; Vidal et al., 2011) . Network-based approaches have been successfully applied to identifying cancer genes Sonachalam et al., 2012) , but the relationships between genomic mutations and global changes in AS are enigmatic. It is now clear that patients with the same cancer type have highly heterogeneous genotypes with diverse genomic alterations (Vogelstein et al., 2013; Zhang et al., 2013) . Therefore, we urgently need methods to assess the impact of patient-specific mutations on AS events from individual tumors to discover personalized driver mutations.
Toward these goals, we developed an integrated, multi-scale framework (hereafter referred to as the Driver mutation-AS interactome Network [DrAS-Net]) ( Figure 1B ) and performed a large-scale systematic investigation of somatic mutationmediated AS patterns across 33 types of cancer. Our integrated analysis revealed widespread AS changes across cancer types. Cancer types with similar tissue origins form clusters based on differential AS patterns. By integrating genomic mutations and AS events into functional association networks, we describe a framework to identify patient-specific potential driver mutations that mediate AS alterations in cancer. The identified driver candidates were enriched in cancer hallmark genes, and cancer subtypes with distinct clinical features could be identified by their AS profiles. In this manner, DrAS-Net provides a valuable approach and resource for detecting candidate driver mutation-mediated AS events in cancer and helps explain the heterogeneity observed across diverse patient populations.
RESULTS

The AS Landscape across Cancer Types
The Cancer Genome Atlas (TCGA) RNA sequencing data provide a valuable resource for investigating AS patterns in cancer. We focused on the AS patterns in >10,000 samples across 33 types of cancer. These cancer types were ordered based on their tissue of origin ( Figure 1C ; Table S1 ). We identified the frequency of AS events per tumor for each cancer type ( Figure 1C ). The average number of AS events per tumor varied considerably among cancer types. In our analysis, AS was categorized into seven classes ( Figure S1A ): exon skipping, alternative donor site, alternative acceptor site, retained intron, mutually exclusive exons, alternative terminator, and alternative promoter. We analyzed the distribution of these AS classes across cancer types and observed that exon skipping was the most frequent class of splice event, while mutually exclusive exons represented a rare class ( Figure S1B ).
Defects in RNA splicing are an important factor contributing to disease, including cancer. We therefore examined differential AS events, defined as significantly altered AS events in cancer compared to normal tissues (see details in Experimental Procedures). We focused on 18 types of cancer, each with more than five normal samples (Wilcoxon rank-sum test, false discovery rate < 0.01). After normalization, our analysis showed a larger proportion of differential AS events in kidney renal clear cell carcinoma (KIRC, n = 5,245) than in other cancer types (Figure 2A ), probably due to elevated expression of splicing factors during renal carcinogenesis (Piekielko-Witkowska et al., 2010) . In contrast, although the number of AS events overall (n = 50,342) was the highest in esophageal carcinoma (ESCA), the fewest (n = 437) differential AS events were identified, suggesting that most AS events in this cancer might be independent of tumor growth. Moreover, we found fewer differential AS events in reproductive system cancers, such as prostate adenocarcinoma (PRAD) and uterine corpus endometrial carcinoma (UCEC), than in most other cancer types. To further explore the distribution of distinct AS classes among these differential AS events, we observed that exon skipping, alternative promoters, and alternative terminators were among the major classes (Figure S1C ), which in total account for 82.86% of the differential AS events ( Figure S1D ). In contrast, only 0.41% (154/37,723) of the cases belonged to the mutually exclusive exons class in the investigated cancer types ( Figure S1D ). Altogether, these results provide evidence for cancer-specific splice isoforms, suggesting widespread splicing perturbations across cancer types.
Cancer Types with Similar Tissue Origins Share Differential AS Patterns Lines of evidence have indicated that cancer types with similar tissue origins share multiple molecular features, such as gene expression, microRNA (miRNA) expression, and DNA methylation (Hoadley et al., 2014; Yang et al., 2016b) . However, whether cancer types with similar tissue origins exhibit similar AS patterns is unknown. To address this question, we computed a paired similarity score based on differential AS events in each Table S1 . cancer ( Figure 2B ). Hierarchical clustering analysis indicated that cancer types with similar tissue origins showed similar differential AS patterns, such as KIRC and kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), colon adenocarcinoma (COAD), and rectum adenocarcinoma (READ). These data also inform long-standing debates regarding appropriate demarcations of ESCA and gastric cancer (STAD), which are clearly separated by differential AS patterns. This result is consistent with a study that demonstrated these two cancer types had distinct molecular characteristics in terms of mRNA expression, miRNA expression, DNA methylation, and copy-number variation (Cancer Genome Atlas Research Network et al., 2017) . Furthermore, cancer types with similar tissue origins cluster together based on different AS classes ( Figures S1E-S1K ). These observations suggest that related mechanisms might operate in cancer types with similar tissue origin.
Specificity and Generality of AS Events in Different Cancer Types
We next investigated the extent to which differential AS events contributed to cancer specificity. We found that differential AS tended to be highly cancer-type specific, because 41.04% (15,482/37,723) of the differential AS events were detected in only one cancer type ( Figure 2C ). To further quantify splicing events, we applied the percent spliced in (PSI) value (Ryan et al., 2016; Wang et al., 2008) , which was defined as the number of reads containing a transcript element divided by the total number of reads, including the AS event. We observed distinct PSI values in tumor samples compared to matched controls. For instance, exon skipping of FGFR1 was detected to be differential in glioblastoma multiforme (GBM) and exhibited high cancer-type specificity ( Figure 2D ). AS of this gene had been demonstrated to be specific in GBM by exon array analysis, and FGFR1 can induce GBM radio-resistance (Cheung et al., 2008) . These results offered a preclinical proof of concept that targeting FGFR1 might be a new method to GBM therapy. In contrast, our analysis also revealed a small subset of genes that were differentially spliced across multiple cancer types. For example, leukocyte-specific protein 1 (LSP1) is an F-actin binding protein, with mutations implicated in many cancer types. Alternative usage of LSP1 promoter had been demonstrated to play critical roles in myogenesis (Ehrlich and Lacey, 2013) . Here, we found that alternative promoter usage of LSP1 occurred in a prevalent manner in 15 types of cancer. Consistently, analysis of the PSI distribution showed lower PSI values in cancer samples compared with normal controls across many cancer types ( Figure 2E ). These results reveal the existence of AS events that are cancer-type specific and those that are prevalent in diverse cancers. For the benefit of the community, the cancer specificity index, as well as the PSI values for AS perturbation events, is provided in Table S2 . This resource can help identify genes and mechanisms that are specific, as well as common, to different cancers for future studies.
AS Perturbation Profiles Predict Immune Signatures in Cancer
To determine which molecular players were associated with the identified AS alterations in cancer, we searched for cellular signaling pathways in tumors with versus without differential AS events, as shown earlier ( Figure 2A ). We compared the gene expression profiles of these tumor samples and used gene set enrichment analysis (GSEA) to identify pathways whose expression levels were enriched or depleted in tumor samples with differential AS perturbations (see details in Experimental Procedures). This analysis was performed across all tumor samples (pan-cancer analysis). Among the pathways upregulated in tumor samples with AS perturbation were those implicated in DNA replication (adjusted p < 0.001) ( Figure S2A ), cell cycle (adjusted p < 0.001) ( Figure S2B ), and DNA repair (adjusted p < 0.001) ( Figure S2C ). These results suggest that there is increased cell proliferation in tumor samples with perturbed AS events. In contrast, most downregulated pathway signatures were associated with the immune system, such as the CD8 T cell receptor pathway (adjusted p = 0.002) ( Figure 2F ), chemokine signaling pathway (adjusted p = 0.002) ( Figure 2G ), and B cell receptor signaling pathway (adjusted p = 0.02) ( Figure 2H ). These observations implicate decreased activity of immune genes in the tumor microenvironment. Moreover, we applied the cell-cycle signature score and immune signature score for each tumor sample, which were defined as the average Figure 2 . The AS Landscape in Human Cancer (A) Number of detected AS events and differential AS events in each cancer. The red line corresponding to the right y axis indicates the total number of AS events detected in each cancer type, while the blue bars corresponding to the left y axis show the number of differential AS events in each cancer (n = 18). The numbering of cancer types on the x axis is the same as in Figure 1. (B) Clustering of cancer types based on the similarity of differential AS patterns. This similarity is computed as the overlap divided by the minimum number of differential AS events between two cancer types. Red and blue indicate high and low similarity, respectively. Cancer types of similar tissue origins are grouped. (C) Distribution of differential AS events over a range of cancer specificity indices. Cancer specificity index is defined as the number of cancer types in which a given differential AS occurs; the lower the index, the more specific. Cancer specificity index ranges from 1 (white) to 15 (blue). (D) Percent spliced in (PSI) index distribution of cancer-type-specific differential AS (FGFR1) events in cancer versus normal samples. PSI index indicates how efficiently sequences are spliced into transcripts. Red boxplots indicate PSI distribution in cancer samples, while blue boxplots indicate PSI distribution in normal samples. (E) PSI index distribution of promiscuous differential AS (LSP1) across multiple cancer types. (F-H) RNA sequencing (RNA-seq) analysis was performed comparing tumors with versus without differential AS events (pan-cancer analysis), considering tumor type as a covariate. GSEA plots, enrichment scores (ESs), and false discovery rates (FDRs; q) are shown for representative gene sets depleted in tumors harboring differential AS events: T cell receptor (F), chemokine signaling (G), and B cell receptor (H) pathways. (I and J) Relationships between the differential AS profiles and the cell-cycle signature (I) and mutation load (J) predictors. In the boxplots, tumors are divided into those that carry perturbed AS events (green) and those that do not (gray). See also Figures S1 and S2 and Table S2 . expression level of the genes involved in each signature. We found that the tumor samples with perturbed AS events exhibited a significantly higher cell-cycle signature score (p = 1.96eÀ10, Wilcoxon rank-sum test) ( Figure 2I ) and lower immune signature score ( Figure S2D ). These results suggest increased cell proliferation and decreased immune activity in tumors with AS perturbation. Moreover, tumor aneuploidy and mutation load had been demonstrated as a possible marker for immune evasion with reduced response to immunotherapy (Davoli et al., 2017) . We thus investigated whether AS perturbation in tumor samples correlated with distinct somatic copynumber alteration (SCNA) levels. We found that tumor samples with altered AS events had significantly higher chromosome SCNA levels (p = 4.2eÀ4, Wilcoxon rank-sum test) ( Figure S2E ), arm SCNA levels (p = 4.6eÀ4, Wilcoxon rank-sum test) (Figure S2F) , and focal and normalized SCNA levels (p < 0.001, Wilcoxon rank-sum test) (Figures S2G and S2H) , as well as a greater number of mutations (p < 2.2eÀ16, Wilcoxon rank-sum test) (Figure 2J) . In summary, our results indicate that AS perturbation in cancer provides a predictor of cytotoxic immune cell infiltration, together with other previously described tumor characteristics such as mutation load and aneuploidy. These observations suggest that AS perturbation profiling may help identify cancer patients most likely to respond to immunotherapy.
DrAS-Net: Network-Based Framework for Identifying Somatic Mutation-Mediated AS across Cancer Types
Our results indicate that there are widespread AS perturbations across cancer types. However, how these AS alterations are determined in cancer is unknown. Because splicing changes may be triggered by genetic mutations , we investigated the extent to which somatic mutations could lead to differential AS of the same or different genomic loci across cancer types. Genes in the cellular system do not function insularly but form functional networks (Cho et al., 2016; Jia and Zhao, 2014) . Thus, we postulated that functional association networks could also be leveraged to relate mutations to their consequent effect on AS alterations. To address this, we first investigated the interactions between differential AS genes and highly mutated genes in the context of functional networks (Rolland et al., 2014) . We observed that the network neighbors of highly mutated genes (defined as the top 20% of genes in each cancer) were enriched in differential AS genes (in 18 types of cancer for which we had sufficient data). In addition, we obtained similar results for the top 15% and 25% of highly mutated genes. These results indicate that mutated genes likely affect the AS alterations of their known interacting partners and suggest that network structure could be used to identify potential regulators of AS events.
We devised a network-based framework to identify mutations that could mediate differential AS events in cancer, referred to as DrAS-Net ( Figure 3A ; Figure S3A ). This model was built upon the idea that gene mutations with functional effects on AS exhibited their impact in the functional association networks. In addition to identifying common somatic mutations that mediate AS in cancer, characterizing personalized genomic mutations in individual cancer patients could reveal new details of complex cancer mechanisms. We therefore identified somatic mutationmediated AS alterations in functional networks for each cancer sample. Next, a greedy optimization approach was used to detect recurrent mutations that can explain most identified AS -alterations in cancer (see details in Experimental Procedures). By applying this method to 33 types of cancer, we identified approximately 60-900 drivers that may determine differential AS events for each cancer type ( Figure 3B ). The total number of drivers varied considerably between cancer types and was largely consistent with earlier results, with LUSC, LUAD, and COAD having higher mutation burdens (Fredriksson et al., 2014) . Moreover, we used three independent methods to validate the inferences of the DrAS-Net ( Figures S3B-S3E and Supplemental Discussion). All these results indicated the network information is valuable for identification of the determinants of AS events.
Network-Based Model Identifies Driver Genes Enriched in Cancer-Related Functions
To investigate whether the network-based method could identify driver genes that were functionally related to cancer, we explored multiple functional features of these genes. So far, the most widely adopted method to identify driver genes is to search for frequently mutated genes within one cancer type (Gonzalez-Perez et al., 2013; Wei et al., 2011) . Although driver genes identified in our analysis were not the most mutated genes, we observed that the mutation frequencies of driver genes were significantly higher than those of randomly selected genes in most (75.8%; 25/33) cancer types (Wilcoxon rank-sum test, p < 0.05) ( Figure 3C ). In addition, the mutation frequencies (A) The network-based framework to identify driver mutations and their mediated AS targets. First, mutation (blue) and differential AS (green) matrices are constructed. Next, patient-specific mutation-mediated AS events are identified based on the functional network structure. All mutation-AS pairs are assembled as a bi-graph, and a greedy search method is used to identify driver mutations and AS events. (E) Enrichment analysis of driver genes for cancer hallmarks. Each column indicates a cancer hallmark-related Gene Ontology (GO) term, while each row indicates a type of cancer. GO terms are ranked based on the hallmarks they belong to. Bigger dots indicate small p values (hypergeometric test). The ten hallmarks from left to right are self-sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, genome instability and mutation, tumor-promoting inflammation, evading immune detection, and reprogramming energy metabolism. The numbering of cancer types (B-E) is the same as in Figure 1 . See also Figure S3 and Table S3 . of driver genes were higher in UCEC and skin cutaneous melanoma (SKCM) than in other cancer types, which may be explained by the higher mutation burden (Kandoth et al., 2013) . We next assessed the functional relevance of these driver genes in cancer by examining the Cancer Gene Census (CGC), a database that catalogs genes for which mutations have been causally implicated in cancer (Forbes et al., 2015) . The candidate driver genes identified here were significantly enriched in CGC genes (hypergeometric test, p < 0.05 in 84.8% or 28/33 cancer types) ( Figure 3D ). Moreover, network analysis revealed that interacting neighbors of candidate driver genes were more enriched in CGC genes than expected by chance (Wilcoxon rank-sum test, p < 0.05 for all cancer types).
To further explore their roles in cancer, we performed functional enrichment analysis of candidate driver genes for cancer hallmarks ( Figure 3E ). This analysis revealed that one or more hallmarks were enriched across different cancer types. Insensitivity to antigrowth signals and evading apoptosis were enriched in almost all cancer types, and reprogramming energy metabolism was enriched in a significant fraction (11/33) of cancer types. Cancer cells with defects in the antigrowth signaling pathway (such as the RB1 and E2F transcription factor mutations identified here) are missing a critical gatekeeper of cell-cycle progression; thus, cancer cells keep growing and dividing (Hanahan and Weinberg, 2011) . Altogether, these results indicate that the network-based method that use both cancer-specific mutation and AS data could identify candidate driver genes that are likely to play a functional role in cancer (Table S3) . Moreover, we found the identified driver candidate mutations had higher Combined Annotation-Dependent Depletion (CADD) scores, had higher conservation, and were depleted in protein domains but were likely to locate in disorder regions and linear motifs (Figures S3F-S3J ; Supplemental Discussion). To investigate whether these mutations led to specific AS outcomes, we transfected HEK293T cells with plasmids encoding for either wild-type genes or identified mutants. Our results suggest that different genetic mutations likely influence distinctly different AS events in cancer ( Figure S3K ; Supplemental Discussion).
Phenotypic Heterogeneity Explained by Somatic
Mutation-Mediated AS Mutations in the same genes are often associated with multiple clinically distinct phenotypes, including different types of cancer. We observed that some mutated genes could influence different AS events across different cancer types ( Figure 4A ). To investigate how mutations in the same genes can cause different types of cancer or different subtypes of the same cancer, we proposed two models for explaining this heterogeneity: Different mutations of the same genes could influence distinct AS events in different patients of the same or different cancer types (model-1 and model-2, respectively, in Figure 4B ). To determine whether the models were responsible for cancer heterogeneity, we compared the similarity in mutation-AS associations between each pair of cancer samples, for both cis-configurations (same gene) and trans-configurations (different genes). We observed that about 99.4% of the mutation-AS pairs were grouped to different mutation-different AS events within the same cancer type ( Figure 4C ), while 99.2% were observed when comparing different cancer types (Wilcoxon rank-sum test, p < 2.2eÀ16) ( Figure 4D ). Altogether, our results indicate that different driver candidate mutations are likely to influence distinct AS perturbations, accounting for different cancer phenotypes.
To determine the extent to which somatic mutations influence AS perturbations in cancer, we first focused on the cis-AS events identified in our study. We found approximately 3.68% of differential AS events to be in the cis-configuration across all cancer types. This proportion was significantly higher than in randomly selected pairs (p < 0.001, randomization test) ( Figure 4E ), suggesting that AS events are likely to be influenced by mutations in the same gene. For instance, IKAROS, encoded by the IKZF1 gene, is a pivotal transcription factor that plays important roles in cancer. We found that several somatic mutations in IKZF1 could influence the AS pattern in cis. In total, five mutations modulated exon 7-9 skipping while four mutations influenced exon 6 skipping in multiple cancer types. Specifically, the mutation A79T influenced an AS event (exon 7-9 skipping) in LUAD, resulting in the loss of the zinc finger type 2-4 domains. 
AS Perturbation Reveals Cancer Subtypes with Distinct Clinical Features
(A) The workflow to discover the clinically associated AS events. The tumor samples in each cancer type were divided into a discovery set and a validation set. Cox regression model was trained using the discovery set and validated in the remaining samples. AS events with a concordance index greater than 0.5 and p value less than 0.05 were identified as clinically associated.
(legend continued on next page)
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Another mutation, G43E, led to exon 6 skipping in LUSC, which caused the loss of the zinc finger type 1 domain ( Figure 4F ). Moreover, the patient with exon 7-9 skipping showed a shorter survival rate. These results suggest that somatic mutations could likely affect the AS profile of the same gene (cis-configuration), and different mutations of the same gene may result in distinct cis-AS alterations. It is known that RNA binding proteins (RBPs) could act in trans to trigger specific AS changes in other genes in several cancer types (Brooks et al., 2015; Sebestyé n et al., 2016) . We obtained 1,348 genes encoding known and predicted RBPs from one of the previous studies (Sebestyé n et al., 2016) . Our analysis showed that the identified driver genes in our study were significantly enriched in RBPs (hypergeometric test, p < 0.05 for 81.2% or 27/33 cancer types) ( Figure 4G) , pointing to the possible role of these driver genes in AS regulation in cancer. Moreover, we integrated the enhanced RNA crosslinking immunoprecipiation followed by sequencing (eCLIP-seq) and short hairpin RNA sequencing (shRNA-seq) datasets to uncover the genome-wide RBP binding profile Van Nostrand et al., 2016) . We found that the mutation-perturbed AS genes we identified were more likely to be RBP targets than the non-perturbed genes (Fisher's exact test, p < 2.2eÀ16) ( Figure 4H ).
Our results have provided insights into possible proteinlevel effects of differential splicing in cancer and have identified perturbations of different types of protein modules that are known to mediate crucial functions. For example, EIF4ENIF1 (also known as 4E-T) has been demonstrated to play critical roles in cancer (Martínez et al., 2015) , and AS of this gene could promote pathological angiogenesis (Chang et al., 2014) . Here, we found that aberrant splicing in EIF4ENIF1 was likely influenced by mutations in the RBP gene EIF4E2 in breast cancer ( Figure 4I ). In cancer patients, different EIF4E2 mutations tended to affect distinct AS events in EIF4ENIF1. For instance, one of the patients harbored the R202Q mutation, which likely mediated the skipping of exon 6-7 of EIF4ENIF1. Loss of these exons caused the elimination of the EIF4ENIF1 nuclear localization signal motif, which is known to impair the nucleocytoplasmic shuttling of EIF4ENIF1 protein, as well as the coupled nuclear import of EIF4E (Dostie et al., 2000) . Therefore, this AS event results in the loss of important EIF4E nuclear functions ( Figure 4J ) (Strudwick and Borden, 2002) . In another patient, the EIF4E2 mutation W148L was identified to influence the skipping of exon 12 of EIF4ENIF1, resulting in the loss of residues 505-527, which do not encompass any known functional sites of the protein. We found that these different AS perturbations were associated with distinct survival rates, with the former patient shorter than the latter one. The former patient was in stage II, while the latter one was in stage I. These results suggest that different mutations result in distinct phenotypes, likely by modulating different AS events. Besides the loss of signal motifs by AS perturbation, we observed in other patients that aberrant splicing might cause loss of signal transduction domains, non-domain functional regions, or catalytic domains in cancer ( Figure S4) . Altogether, our results that link single-nucleotide mutations to AS events can provide mechanistic insights into how mutations can result in cancer progression. It also suggests that the identification of AS profiles mediated by patientspecific mutations could be a valuable strategy and resource to help explain the phenotypic heterogeneity in the same or different cancer types.
Mutation-Mediated AS Identifies Cancer Subtypes Associated with Distinct Survival Rates
To explore the prognosis potential of AS events, we first divided the tumor samples into a discovery set and a validation set. The Cox regression model was trained using the discovery dataset, and the trained model was validated in validation set ( Figure 5A ). The AS events identified by DrAS-Net with a concordance index larger than 0.5 and a p value less than 0.05 were identified as clinically associated AS events ( Figure S5A ). Next, we grouped cancer samples based on these AS events using consensus clustering (Wilkerson and Hayes, 2010) . In total, we found that a considerable fraction (36.4%; 12/33) of cancer types can be grouped into subtypes with distinct survival rates. In addition, we randomly grouped samples into the same number of subtypes as consensus clustering, and then the survival rates were compared with a log rank test. As a result, we also observed that the p values were significantly less than those of random conditions in most cancer types (p values < 0.05) ( Figure 5B ). These results indicate that the driver AS events may be promising biomarkers in these cancer types.
For example, this analysis revealed five subtypes in liver hepatocellular carcinoma (LIHC, n = 371) ( Figure 5C ; Figures S5B and  S5C) . Patients of the same subtype were distributed among different tumor stages ( Figure S5D ), indicating that the AS-based classification is independent of the tumor stage. A large-scale study found that a high BMI was associated with an increase in liver cancer risk (Campbell et al., 2016) . We thus explored whether cancer patients within different subtypes had distinct weight profiles. We observed that patients in the subtype-2 group had significantly higher weight than other subtypes (Figure S5E ). There was a significant difference in the overall survival of patients among these subtypes (log rank test, p = 4.61eÀ3) (B) The survival differences of different cancer subtypes revealed by AS clustering analysis. The cancer samples are randomly divided into the same number of subtypes as revealed by AS clustering, and the survival difference p values are calculated by log rank test. See also Figure S5 and Table S4 .
( Figure 5D ). Specifically, patients in the subtype-1 and subtype-3 groups had a shorter survival time. Next, we investigated whether the AS events in each subtype were driven by distinct mutated genes. As shown in Figure 5E , we observed that only four mutated genes were shared in these five subtypes. Functional enrichment analysis also suggested that these mutated genes of different subtypes were enriched in different functions; for example, genes in cluster 1 were enriched in the tumor necrosis factor (TNF) signaling pathway, whereas mutated genes in cluster 3 were enriched in viral carcinogenesis (Table S4) . As another validation, we clustered lower grade glioma (LGG) (n = 514) samples based on mutation-mediated AS events. Clustering analysis revealed five subtypes ( Figure 5F ) with significantly different survival patterns (log rank test, p < 2.2eÀ16) (Figure 5G) . Moreover, we found these to be distinct subtypes with distinct age of onset ( Figure S5H ) and with mutated genes enriched in different pathways ( Figure S5I ). Furthermore, our results suggest that profiling AS events is an important strategy for subtype stratification, which is independent of gene expression deregulation in cancer ( Figures S5J and S5K) . Altogether, our data reveal critical driver mutations and important clinical and biological trends associated with AS in cancer, and they suggest a putative molecular mechanism for mutation-mediated regulation of specific AS events.
DrAS-Net Interface: A User-Friendly Online Tool to Explore Mutation-AS Relationships in Cancer
To help researchers apply the principles described in this work on any mutation or AS of interest, we have developed a comprehensive and interactive web resource in DrAS-Net (Table S5 ) (http://www.bio-bigdata.com/dras_net/). The features provided in the resource, which will be continuously updated, should serve as a guide for biologists interested in identifying the genetic determinants of splicing specificity for various applications (for example, RNA editing and pleotropic studies) and understanding the consequences of mutations (for example, driver mutations and natural variation) in cancer patients and healthy individuals.
DISCUSSION
In this study, we have performed a systematic characterization of AS across various cancer types and reveal widespread AS perturbations in human cancers. Cancer types with similar tissue origins share common differential AS patterns. Although most AS events are cancer-type specific (such as FGFR1), some genes (such as LSP1 and KRT222) show consistent AS alterations across various types of cancer. This points to the existence of cancer-specific and general mechanisms that might contribute to disease progression. Strikingly, we have found that tumors with aberrant splicing isoforms tend to exhibit decreased expression levels of immune system-related genes and increased expression levels of cell-cycle marker genes. This provides potential immune markers and promising targets for immunotherapy in diverse cancer types. Altogether, the comprehensive AS perturbation landscape identified here provides a valuable resource for further mechanistic and functional studies for the research community (Table S5) .
Given the widespread AS perturbations in cancer, it is important to determine how these AS events are mediated. Previous studies have suggested AS alterations in cancer may be caused by changes in expression, amplification, and deletions in splicing factors and RBPs (Oltean and Bates, 2014; Sebestyé n et al., 2016) . Another possibility is alteration in DNA methylation and chromatin modifications, which has been observed to be responsible for AS aberration (Lev Maor et al., 2015) . Moreover, some case studies have demonstrated that the AS events are influenced by genomic mutations. But how somatic mutations mediate AS events on a pan-cancer scale was unknown. Here, we developed a network-based framework, DrAS-Net, to identify to what extent the observed AS perturbations are regulated by somatic mutations. The application of our method to 33 types of cancer reveals mutation-AS functional associations for each cancer patient. In contrast to frequency-based approaches, network-based methods can detect moderately or even rarely mutated genes with functional relevance. In addition, identifying patient-specific driver mutations and the AS events they influence can provide mechanistic insights and enables a more personalized approach for cancer treatment.
We provide insights into possible functional consequences of losing crucial protein modules (catalytic domains, signaling domains, functional regions, and short linear motifs) due to differential AS events in cancer that are mediated by somatic mutations (Figure 4 ; Figure S4 ). These results indicate that deregulation of AS may rewire cellular networks or signaling pathways in cancer. Yang et al. (2016a) investigated the interaction profiles of different isoforms and proposed a central role for AS in network organization in different tissues of healthy individuals. However, the drivers of this reorganization, i.e., how interaction networks or signaling pathways are perturbed in specific cancer patients, remains to be discovered. In this context, our study reveals that mutation-mediated AS events can serve as valuable biomarkers for cancer subtype stratification. Further analyses in LIHC and LGG demonstrate that these AS subtypes have distinct survival rates. In addition, compared with transcriptome-based cancer subtypes, we found that these AS-based subtypes are not driven by gene expression. These observations suggest that subtype-specific AS events are an independent and informative measure for cancer subtyping. Based on the observation that AS events in each cancer subtype are influenced by distinct mutations, we have proposed two models to help interpret the phenotypic heterogeneity. Many identified mutation-AS events occur in a patient-specific manner, indicating that somatic mutations are likely an important component in determining patient-specific splicing perturbation and tumorigenesis. Furthermore, our finding that cancer patients with AS perturbations exhibit reduced immune signature has provided insights into strategies for potential immunotherapy. For instance, differential AS profiles of specific membrane proteins in cancer can be exploited for defining epitopes for chimeric antigen receptor (CAR) T cell development and design for cancer therapy.
In summary, we have systematically characterized the widespread AS perturbations across cancer types and presented a patient-specific mutation-AS network analysis method to prioritize cancer driver genes and mutations. Our method and results will be useful for investigators who explore cancer genes through rapidly emerging next-generation sequencing applications in cancer research and personalized medicine. We hope that the resource that we provide in this study will inspire several future investigations in diverse cancer types.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in Supplemental Experimental Procedures.
Construction of DrAS-Net
We developed an integrated analysis framework to identify the mutationmediated AS in cancer. This approach relates genomic mutations to AS patterns, informed by known interactions between genes. First, the genomic mutations in 10,489 samples across 33 types of cancer were downloaded from the TCGA website. For each cancer, we transformed these mutations into a gene-patient matrix, M(i,j), which represents a binary matrix to indicate whether the mutations were observed in a specific patient:
Mði; jÞ = 1; if gene i mutated in patient j 0; if gene i not mutated in patient j :
Next, the AS datasets in each cancer were converted to another gene-patient matrix, AS (i,j) . This matrix indicates whether the AS of gene i in patient j is different from the population-level PSI distribution for that gene. Whenever an AS event in a specific sample was defined as differential, we followed these rules:
ASði; jÞ = where Q3 and Q1 were the 75th and 25th percentiles of PSI distribution across all cancer samples. We hypothesized that if the mutated genes in a patient can affect the AS of other genes, they should have some functional links in known functional networks. Thus, for each patient Pk, we identified the gene pair gi-gj that satisfied the following three rules: gi is mutated; gj exhibits differential AS, and gi and gj interact according to known protein-protein interaction (PPI). Here, a systematic unbiased map of $14,000 high-quality human functional interactions was used in our analyses (Rolland et al., 2014) . Then we integrated all gene pairs in each patient and constructed the mutation-mediated AS network in each cancer. In addition, these pairs were divided into cis-and trans-regulation. If the same gene is mutated and with different AS in the same patient, we considered this to be cis-regulation; otherwise, it was seen as trans-regulation.
After assembling all mutated gene-AS associations in each patient, we constructed a bipartite network for each cancer. Next, we prioritized the mutated genes by identifying genes with the largest AS disruption in cancer. The mutated genes in each bipartite network were ranked by degree (the number of mis-spliced events they mediate), and then for each iteration, we calculated the saturation index (S) of perturbed AS events, defined as the obtained mutation-mediated AS events divided by the total number of perturbed AS events in cancer. We chose a mutated gene that covered the largest number of perturbed AS events. The greedy algorithm was stopped when all AS events were covered. Then, the mutations in the identified genes in the corresponding sample were assembled as driver mutations in each cancer. This prioritization was only applied to trans-regulations. All cis-regulated mutations were added to the driver list ( Figure S3A ). We developed a web interface to host DrAS-Net (http://www.bio-bigdata.com/dras_net/index.jsp) that includes a summary of the features in DrAS-Net, describing mutation-induced splicing perturbation profiles in cancer. These features allow users to investigate various aspects of splicing specificity and patient mutation-specific perturbation information across all human cancer types. The R scripts to perform this process can be accessed from GitHub (https://github.com/lyshaerbin/DrASNet). 
